Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Nanoscale drug discovery approach relies on in silico, in vivo, in vitro

By Drug Discovery Trends Editor | October 10, 2012

 

Gd@C82(OH)22 is a spherical cage of carbon atoms (blue) with active hydroxyl groups dangling on the outside (red and white) and an atom of gadolinium trapped on the inside (purple). Originally developed for medical imaging, these nanoparticles now show promise for treating pancreatic cancer. Image: IBM

The medical community is armed with new insights and new options for drug design and discovery to treat fatal diseases such as pancreatic cancer. Using in silico computational tools to complement the results of in vivo and in vitro experiments, researchers revealed an atomic-level understanding of the mechanism by which nanoparticles inhibit the growth and metastasis of pancreatic tumors.

The nanoparticle type at the center of this study is gadolinium metallofullerenol, or Gd@C82(OH)22, which was originally developed for medical imaging applications such as MRI. Also central to the study are two popular anticancer therapy targets, MMP-2 and MMP-9. These MMPs, or matrix metalloproteinases, are key to the survival of cancer cells because they help bring a supply of blood vessels, and therefore oxygen and nutrients, to tumor sites.

Experiments showed that nanoparticle therapy blocked pancreatic tumor growth in mice and, at the cellular level, suppressed the expression and reduced the activities of MMP-2 and MMP-9. Computational simulations revealed that the nanoparticles’ action on MMP-9 is indirect such that they bind to the protein far from its active site. This is in distinct contrast to traditional molecular medicines that typically target the MMP active metal-binding site, directly blocking it or damaging the protein’s structure.

The nanoparticles were so effective that the team’s data suggest they may be a better pancreatic cancer therapy option than traditional medicines. Moreover, the team’s integrated use of computational theory to complement experimental data offers a new understanding, with unprecedented mechanistic detail, of the interactions between nanoparticles and biological molecules, bringing us into uncharted and promising new territory for drug design and discovery.

Molecular mechanism of pancreatic tumor metastasis inhibition by Gd@C82(OH)22 and its implication for de novo design of nanomedicines

Source: Pacific Northwest National Laboratory


Filed Under: Drug Discovery

 

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE